In recent years, many studies support the use of dual-HER2 blockade for neoadjuvant treatment of HER2-positive breast cancer patients, regardless of whether lapatinib (13, 14) or pertuzumab was used as a second agent (15). This evidence concerns the gene ERBB2 and breast carcinoma.